Last reviewed · How we verify
No low molecular weight heparin
No low molecular weight heparin works by inhibiting Factor Xa and thrombin.
No low molecular weight heparin works by inhibiting Factor Xa and thrombin. Used for Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery, Treatment of acute deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | No low molecular weight heparin |
|---|---|
| Also known as | No enoxaparin |
| Sponsor | Beijing Anzhen Hospital |
| Drug class | Anticoagulant |
| Target | Factor Xa and thrombin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
It achieves this by binding to antithrombin and enhancing its ability to inactivate Factor Xa and thrombin, thus preventing blood clot formation.
Approved indications
- Prevention of deep vein thrombosis and pulmonary embolism in patients undergoing major orthopedic surgery
- Treatment of acute deep vein thrombosis and pulmonary embolism
Common side effects
- Bleeding
- Hypersensitivity reactions
- Osteoporosis
Key clinical trials
- The Intensive Care Platform Trial (PHASE4)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
- Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT) (NA)
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis (PHASE3)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Anticoagulation-free VV ECMO for Acute Respiratory Failure (PHASE2, PHASE3)
- Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No low molecular weight heparin CI brief — competitive landscape report
- No low molecular weight heparin updates RSS · CI watch RSS
- Beijing Anzhen Hospital portfolio CI